Natasha Murphy is the director of Health Policy at American Progress, where she develops and advances policy proposals to lower health care costs and improve health care coverage, affordability, and quality.
Prior to joining American Progress, Murphy served as a public policy and regulatory compliance analyst at CareFirst BlueCross BlueShield, where she leveraged her research, analysis, and communication skills to inform and disseminate the organization’s policy positions and served as a liaison for regulatory and policy issues affecting the commercial market. Previously, Murphy was a Kaiser Family Foundation Barbara Jordan Health Policy Scholar, assisted with early Affordable Care Act implementation efforts at the District of Columbia Department of Health Care Finance, and served as an ombudsman for the District of Columbia deputy mayor for health and human services.
Murphy earned her Master of Science in public health, health policy degree at the Johns Hopkins Bloomberg School of Public Health and Bachelor of Science in health sciences, magna cum laude, from Howard University.
A historic Senate proposal would rein in prescription drug prices and make drug costs more affordable for families.
To manage rising prescription drug prices, states should explore comprehensive policy options that address cost drivers across the drug supply chain.
As the conclusion of the national public health emergency looms, state and federal policymakers should improve continuity of care for millions of Medicaid enrollees facing disenrollment and preserve critical access to COVID-19 testing and treatment.
Data show that in just one year, the 2021 American Rescue Plan eased hardship for millions of Americans and demonstrated the need for further federal investment to build a long-term, equitable economy that works for all.
The Center for American Progress wrote a comment letter to the U.S. Department of Health and Human Services and the Department of the Treasury on the impact of changes in federal law and policy on the Georgia Access Model’s compliance with statutory guardrails.
The House-passed bill expands insurance coverage, reduces prescription drug costs, and makes crucial investments in maternal and public health.
